Press Release |
25 January 2013 |
Avacta Group plc
("Avacta" or "the Group")
Result of AGM
Avacta Group plc (AIM:AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, announces that at its Annual General Meeting held today, all resolutions put to shareholders were duly passed.
- Ends -
For further information please contact:
Avacta Group plc |
|
Alastair Smith, Chief Executive Officer |
Tel: +44 (0) 844 414 0452 |
Tim Sykes, Chief Financial Officer |
|
|
|
Broker and Nominated Adviser Panmure Gordon (UK) Limited |
Tel: +44 (0) 20 7886 2500 |
Fred Walsh / Andrew Burnett / Grishma Patel Charles Leigh-Pemberton (Corporate broking) |
|
Media Enquiries - Abchurch Communications |
|
Sarah Hollins / Adam Michael / Harriet Rae |
Tel: +44 (0) 20 7398 7718 |
Notes to Editors:
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.
Avacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.
The cost of healthcare is driven by many factors. New drugs are expensive to develop, most that start the development process never reach the patient, and those that do are often very costly to prescribe. Inadequate, incorrect and slow diagnosis of disease cause delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.
Avacta is dedicated to reducing global healthcare costs. It does this through developing and providing innovative and practical tools to help drug developers get their products to market faster and more reliably, and to provide clinicians with rapid and powerful diagnostics to improve patient treatment.
Avacta joined AIM in August 2006 and is based in Wetherby, UK.
For further information visit www.avacta.com